Leprosy is an infectious disease caused by Mycobacterium leprae, which is a noncultivable bacterium. One of the principal goals of leprosy research is to develop serological tests that will allow identification and early treatment of leprosy patients. M. habana is a cultivable nonpathogenic mycobacterium and candidate vaccine for leprosy, and several antigens that cross-react between M. leprae and M. habana have been discovered. The aim of the present study was to extend the identification of cross-reactive antigens by identifying M. habana proteins that reacted by immunoblotting with antibodies in serum samples from leprosy patients but not with antibodies in sera from tuberculosis (TB) patients or healthy donors (HDs). A 28-kDa antigen that specifically reacted with sera from leprosy patients was identified. To further characterize this antigen, protein spots were aligned in two-dimensional polyacrylamide gels and Western blots. Spots cut out from the gels were then analyzed by mass spectrometry. Two proteins were identified: enoyl-coenzyme A hydratase (lipid metabolism; ML2498) and antigen 85B (Ag85B; mycolyltransferase; ML2028). These proteins represent promising candidates for the design of a reliable tool for the serodiagnosis of lepromatous leprosy, which is the most frequent form in Mexico.Intradermal immunization with killed Mycobacterium leprae renders mice immune to infection with viable M. leprae (28). This protection is long lasting and systemic. However, when other mycobacteria are used to immunize mice against infection with viable M. leprae bacilli, they have been shown to be either ineffective (i.e., Mycobacterium duvalii) or to confer only partial protection (i.e., M. bovis BCG) (29). In 1985 and then 1989, Mycobacterium habana TMC 5135 was found to be as effective as M. leprae in protecting mice against footpad infection (32, 33). This was surprising, since Shepard et al. found that among a large panel of mycobacteria tested, only M. leprae and BCG were able to confer protection (30).M. habana was first described following its isolation from 35 cases of pulmonary tuberculosis (TB) (40); subsequently, it was found to be closely related to the species Mycobacterium simiae serovar 1 and is now known as M. simiae serotype 1 (20). In 1996, Khoo et al. demonstrated that M. habana TMC 5135 and several M. simiae strains differed in their polar glycopeptidolipid (GPL) compositions, conferring sufficient specificity for identification of M. habana as a distinct serotype of M. simiae (14).M. habana is a cultivable organism, protects mice against Mycobacterium ulcerans challenge, and offers consistent protection against infection with Mycobacterium tuberculosis H37Rv and other strains of M. tuberculosis (11,12). Some studies suggest that the secretory antigens released by actively growing M. habana bacilli are protective against M. tuberculosis infections (6,8). Recent experimental data indicate that M. habana TMC 5135 and M. habana IPK-220 strains, which differ in the fine structure of their mycolates, a...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.